{"doi":"10.1210/clinem/dgad702","title":"Effect of Anamorelin, a Ghrelin Receptor Agonist, on Muscle and Bone in Adults With Osteosarcopenia","abstract":"CONTEXT: Anamorelin, a ghrelin receptor agonist known to stimulate the pulsatile release of GH from the pituitary, has the potential to improve musculoskeletal health in adults with osteosarcopenia. OBJECTIVE: To determine the effect of anamorelin treatment for 1 year on muscle mass and strength and on biochemical markers of bone turnover in adults with osteosarcopenia (OS). DESIGN: Randomized, placebo-controlled, 1-year anamorelin intervention trial. SETTING: The Bone Metabolism Laboratory at the USDA Nutrition Center at Tufts University. PARTICIPANTS: 26 men and women, age 50 years and older, with OS. MAIN OUTCOME MEASURES: Muscle mass by D3-creatine dilution and lean body mass (LBM) and bone mineral density (BMD) by dual-energy X-ray absorptiometry, muscle strength, serum IGF-1, and bone turnover markers, serum procollagen 1 intact N-terminal (P1NP), and C-terminal telopeptide (CTX). RESULTS: Anamorelin did not have a significant effect on muscle mass or LBM; it significantly increased knee flexion torque at 240°/s by 20% (P = .013) and had a similar nonstatistically significant effect on change in knee extension; it increased bone formation (P1NP) by 75% (P = .006) and had no significant effect on bone resorption (CTX) or BMD. Serum IGF-1 increased by 50% in the anamorelin group and did not change in the placebo group (P = .0001 for group difference). CONCLUSION: In this pilot study, anamorelin did not significantly alter muscle mass; however, it may potentially improve lower extremity strength and bone formation in addition to increasing circulating IGF-1 levels in adults with OS. Further study of anamorelin in this population is warranted.","journal":"The Journal of Clinical Endocrinology & Metabolism","year":2023,"id":371898,"datarank":0.4342123198723589,"base_score":1.9459101490553132,"endowment":1.9459101490553132,"self_citation_contribution":0.29188652235829704,"citation_network_contribution":0.14232579751406188,"self_endowment_contribution":0.29188652235829704,"citer_contribution":0.14232579751406188,"corpus_percentile":null,"corpus_rank":null,"citation_count":6,"citer_count":5,"citers_with_citation_signal":4,"citers_with_endowment":4,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9636,"is_data_producer":true,"deposit_databanks":{"ClinicalTrials.gov":["NCT 04021706"]},"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2023-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":276342,"name":"Kathryn Barger","orcid":null,"position":1,"is_corresponding":false},{"id":1131940,"name":"Elise Reitshamer","orcid":"0000-0002-5219-8288","position":2,"is_corresponding":false},{"id":109419,"name":"Roger A. Fielding","orcid":"0000-0003-2236-9020","position":3,"is_corresponding":false},{"id":278796,"name":"William J. Evans","orcid":"0000-0001-6757-1471","position":4,"is_corresponding":false},{"id":462282,"name":"Lisa Ceglia","orcid":"0000-0003-0023-3640","position":5,"is_corresponding":false},{"id":249042,"name":"Bess Dawson‐Hughes","orcid":"0000-0003-3136-0386","position":0,"is_corresponding":true}],"reference_count":47,"raw_metadata":null,"created_at":"2026-07-19T01:15:49.453761Z","pmid":"38057159","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}